Anavex Life Sciences (US:AVXL) Globenewswireยท2025-05-14 11:30Core Viewpoint - Anavex Life Sciences Corp. is actively participating in two upcoming investor conferences, showcasing its focus on developing innovative treatments for various neurodegenerative and neurodevelopmental disorders, including Alzheimer's and Parkinson's diseases [1][2]. Company Overview - Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to developing novel therapeutics for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders [2]. - The company's lead drug candidate, ANAVEX2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer's disease and is also being studied for Parkinson's disease dementia and Rett syndrome [2]. - ANAVEX2-73 is designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors, with preclinical studies indicating its potential to halt or reverse Alzheimer's disease [2]. - The company is also developing ANAVEX3-71, which targets SIGMAR1 and M1 muscarinic receptors, showing promise in addressing cognitive deficits and other hallmarks of Alzheimer's disease in preclinical trials [2]. Upcoming Events - Anavex's President & CEO, Christopher U. Missling, PhD, will participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 2:30 pm ET [1]. - The company will also be present at the H.C. Wainwright 6th Annual Neuro Perspectives Conference on June 17, 2025, at 7:00 pm ET [1].